Article
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
2 Mar 2023
Abstract excerpt
Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, we analyze a pan-cancer cohort (META-PRISM) of 1,031 refractory metastatic tumors profiled via whole-exome and transcriptome sequencing. META-PRISM tumors, particularly prostate, bladder, and pancreatic types, displayed the most...
Topics
Join the communities discussing this publication.